Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis (Q28742423)

human immunodeficiency virus infectious disease

inferred from abstract

1 reference

1 July 2020

HIV protease inhibitors

1 reference

2 October 2019

4

0 references

Eugènia Negredo

5

Eugenia Negredo

0 references

Jose R. Arribas

Jose Arribas

10

0 references

Federico Pulido

Federico Pulido

3

0 references

Pedro Cahn

8

Pedro Cahn

0 references

author name string

Sandra Mathis

1

0 references

Bettina Khanlari

2

0 references

Mark Nelson

6

0 references

Pietro Vernazza

7

0 references

Jean-Luc Meynard

9

0 references

Heiner C Bucher

Creative Commons Attribution 4.0 International

11

0 references

language of work or name

English

0 references

publication date

19 July 2011

8 references

23 March 2019

22 June 2019

2 October 2019

19 October 2019

26 April 2020

1 July 2020

21 October 2022

25 October 2022

8 references

23 March 2019

22 June 2019

2 October 2019

19 October 2019

26 April 2020

1 July 2020

21 October 2022

25 October 2022

6

0 references

issue

7

0 references

page(s)

e22003

0 references

copyright license

8 references

23 March 2019

22 June 2019

2 October 2019

19 October 2019

26 April 2020

1 July 2020

21 October 2022

on focus list of Wikimedia project

25 October 2022

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

Measuring inconsistency in meta-analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3139616

Quantifying heterogeneity in a meta-analysis

17 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3139616

Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis

17 March 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3139616

17 March 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3139616

Meta-analysis in clinical trials

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3139616

Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial

17 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3139616

Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3139616

Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3139616

Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3139616

A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3139616

Designing and interpreting HIV noninferiority trials in naive and experienced patients

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3139616

Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3139616

Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3139616

A phase II trial of dual protease inhibitor therapy: amprenavir in combination with indinavir, nelfinavir, or saquinavir

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3139616

Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3139616

Trials to assess equivalence: the importance of rigorous methods

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3139616

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

3 June 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0022003

Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0022003

Efficacy of experimental treatments compared with standard treatments in non-inferiority trials: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0022003

Quality of reporting of noninferiority and equivalence randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0022003

Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0022003

Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0022003

A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0022003

Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0022003

Monotherapy with Lopinavir/Ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0022003

The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0022003

Saquinavir/ritonavir monotherapy as a new nucleoside-sparing maintenance strategy in long-term virologically suppressed HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0022003

Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0022003

First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0022003

Discordance Between Cerebral Spinal Fluid and Plasma HIV Replication in Patients with Neurological Symptoms Who Are Receiving Suppressive Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0022003

Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3139616

A pilot study of switch to lopinavir/ritonavir (LPV/r) monotherapy from nonnucleoside reverse transcriptase inhibitor-based therapy

27 November 2018

1 reference

12 December 2020

Current issues in non-inferiority trials

1 reference

12 December 2020

Antiretroviral monotherapy: should we abandon the principles of successful antiretroviral therapy?

1 reference

12 December 2020

Randomized, double-blind trial comparing indinavir alone, zidovudine alone and indinavir plus zidovudine in antiretroviral therapy-naive HIV-infected individuals with CD4 cell counts between 50 and 250/mm3

1 reference

12 December 2020

The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine. Prometheus Study Group

1 reference

12 December 2020

Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Prometheus Study Group

1 reference

12 December 2020

10.1371/JOURNAL.PONE.0022003

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

4462281

ADS bibcode

2011PLoSO...622003M

0 references

OpenCitations bibliographic resource ID

4462281

1 reference